Search results for "Platelet Aggregation"

showing 10 items of 155 documents

Spontaneous echo contrast imaging in infective endocarditis: a predictor of complications?

1992

Infective endocarditis is associated with significant morbidity and mortality. Valvular destruction and congestive heart failure are more common in patients with echocardiographically detectable vegetations. In addition, spontaneous platelet aggregation is increased when vegetations are present on cardiac valves. The aim of the study was to assess the prognostic value of spontaneous echo contrast (SEC) imaging, as SEC is supposed to reflect red blood cell aggregates stimulated by platelet activity. We studied 293 patients with clinical signs of infective endocarditis. Vegetations, attached to the aortic or mitral valve, were found in 130 patients (44.4%) who were followed for a mean period …

AdultMalemedicine.medical_specialtyPlatelet Aggregationmedicine.medical_treatmentValve replacementPredictive Value of TestsRisk FactorsInternal medicineMitral valvemedicineEndocarditisHumansRadiology Nuclear Medicine and imagingPlatelet activationSpontaneous platelet aggregationAbscessbusiness.industryEndocarditis BacterialMiddle Agedmedicine.diseasePrognosismedicine.anatomical_structureEchocardiographyInfective endocarditisHeart failureCardiologyFemaleCardiology and Cardiovascular MedicinebusinessInternational journal of cardiac imaging
researchProduct

Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus.

2004

Abstract Triflusal is an antiplatelet drug related to aspirin, with different pharmacological properties and a lower haemorrhagic risk. We aimed at comparing their effects on platelet and endothelial activation in type 2 diabetes mellitus (T2DM). In a randomized, double-blind, parallel group study, we compared the effects of three daily regimens (300, 600, and 900mg) of triflusal, and aspirin (100mg/day) on urinary 11-dehydro-thromboxane (TX)B 2 , index of in vivo platelet activation, ex vivo platelet function using the analyzer PFA-100, plasma von Willebrand factor (vWF), P-selectin, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and serum nitrite a…

AdultMalemedicine.medical_specialtyThromboxaneaspirinRadioimmunoassaychemistry.chemical_compoundThromboxane A2Von Willebrand factorDouble-Blind MethodInternal medicinetype 2 diabetes triellitusvon Willebrand Factormedicineplatelet activationHumansPlateletPlatelet activationAgedRetrospective StudiesAspirinbiologyDose-Response Relationship DrugMiddle AgedSalicylatesThromboxane B2Thromboxane B2triflusalP-SelectinEndocrinologychemistryDiabetes Mellitus Type 2biology.proteinTriflusalFemaleCardiology and Cardiovascular MedicineBiomarkersPlatelet Aggregation Inhibitorsmedicine.drugFollow-Up Studies
researchProduct

Immediate versus delayed facilitated percutaneous coronary intervention. A pilot study

2005

The study was aimed to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI <2 hours, and in patients initially successfully treated with pharmacological therapy and delayed PCI (12-72 hours). All patients had to have successful reperfusion, to receive the combination of a standard abciximab infusion plus half dose rtPA. Similar results were observed in both groups. Delayed PCI group showed a favorable trend in restenosis and bleedings (ns) and a significant reduced angiographic evidence of thrombus formation in IRA. Our very preliminary data suggest the safety and possible use of delayed facilitated PCI in patients with STEMI. The studied …

AdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentAbciximabMyocardial InfarctionMyocardial IschemiaEligibility DeterminationMyocardial ReperfusionPilot ProjectsAcute myocardial infarctionElectrocardiographyImmunoglobulin Fab FragmentsRestenosisInternal medicinemedicineAbciximabHumansIn patientcardiovascular diseasesThrombusAngioplasty Balloon CoronaryFacilitated pciDelayed percutaneous coronary interventionPharmacologybusiness.industryPatient SelectionPercutaneous coronary interventionAntibodies MonoclonalMiddle Agedmedicine.diseaseSurvival RateGIIb/IIIa inhibitorssurgical procedures operativeTreatment OutcomeTissue Plasminogen ActivatorConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessFacilitated percutaneous coronary interventionTIMIPlatelet Aggregation InhibitorsCombined therapymedicine.drug
researchProduct

Patent foramen ovale closure in stroke patients with migraine in the CLOSE trial. The CLOSE-MIG study.

2021

International audience; Background and purpose The efficacy of patent foramen ovale (PFO) closure to reduce the frequency of migraine attacks remains controversial. Methods This was a planned sub-study in migraine patients enrolled in a randomized, clinical trial designed to assess the superiority of PFO closure plus antiplatelet therapy over antiplatelet therapy alone to prevent stroke recurrence in patients younger than 60 years with a PFO-associated cryptogenic ischaemic stroke. The main outcome was the mean annual number of migraine attacks in migraine patients with aura and in those without aura, as recorded at each follow-up visit by study neurologists. Results Of 473 patients randomi…

Adultmedicine.medical_specialtyStroke patientAuraSeptal Occluder Device[SDV]Life Sciences [q-bio]Migraine DisordersForamen Ovale PatentBrain Ischemia03 medical and health sciences0302 clinical medicineInternal medicineIschaemic strokemedicineHumans030212 general & internal medicineClosure (psychology)Foramen ovale (heart)business.industryMiddle Agedmedicine.diseaseClinical trialStrokemedicine.anatomical_structureTreatment OutcomeNeurologyMigraineCardiologyPatent foramen ovaleFemaleNeurology (clinical)business030217 neurology & neurosurgeryPlatelet Aggregation InhibitorsEuropean journal of neurologyREFERENCES
researchProduct

Platelets, eicosanoids and aging.

1992

Aged 80 and overBlood Plateletsmedicine.medical_specialtyAgingPlatelet AggregationGeriatrics gerontologybusiness.industrymedicine.diseaseThrombosisEndocrinologyInternal medicinemedicineBlood VesselsEicosanoidsHumansPlateletGeriatrics and GerontologybusinessAgedAging (Milan, Italy)
researchProduct

Prostacyclin receptor desensitization is a reversible phenomenon in human platelets.

1997

Background Long-term exposure of platelets to endogenous or exogenous prostacyclin or its analogues might result in desensitization of the platelet prostacyclin receptor in vitro and in vivo accompanied by a loss in receptor density on the platelet surface and a reduced sensitivity toward the inhibitory effects of prostacyclins. However, the reversibility of this process in platelets has not yet been investigated. Methods and Results Human platelets desensitized by the chemically stable prostacyclin analogue iloprost showed a significant reduction in [ 3 H]-iloprost binding sites that was reversed by saponin permeabilization. This indicates functionally active internalized prostacyclin rec…

AgonistBlood PlateletsMalemedicine.medical_specialtyCell Membrane Permeabilitymedicine.drug_classReceptors ProstaglandinProstaglandinProstacyclinReceptors EpoprostenolProstacyclin receptor bindingchemistry.chemical_compoundReference ValuesPhysiology (medical)Internal medicinemedicineCyclic AMPHumansPlateletIloprostProstacyclin receptorbusiness.industryEndocrinologychemistrycardiovascular systemPlatelet aggregation inhibitorlipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugIloprostCirculation
researchProduct

Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function

2014

Pathogen reduction (PR) systems for platelets, based on chemically induced cross-linking and inactivation of nucleic acids, potentially prevent transfusion transmission of infectious agents, but can increase clinically significant bleeding in some clinical studies. Here, we documented the effects of PR systems on microRNA and mRNA levels of platelets stored in the blood bank, and assessed their impact on platelet activation and function. Unlike platelets subjected to gamma irradiation or stored in additive solution, platelets treated with Intercept (amotosalen + ultraviolet-A [UVA] light) exhibited significantly reduced levels of 6 of the 11 microRNAs, and 2 of the 3 anti-apoptotic mRNAs (B…

AmotosalenBlood Plateletstransfusion medicineplatelet functionbcl-X ProteinEndogenyPharmacologyHumansPlateletPlatelet activationRNA MessengerMean platelet volumeplateletClusterinbiologypathogen reductionGene Expression ProfilingImpaired platelet aggregationRNAMicroRNAHematologyGeneral MedicinePlatelet ActivationMolecular biologyMicroRNAsClusterinBlood Preservationbiology.proteinOriginal ArticleTranscriptomeMean Platelet VolumePlatelets
researchProduct

Initiation and duration of dual antiplatelet therapy after inpatient percutaneous coronary intervention with stent implantation in Germany: An electr…

2017

Abstract Background Studies assessing the routine outpatient dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in Germany are scarce. The aim of this study was (i) to investigate the initiation and duration of DAPT after inpatient PCI with stent implantation in Germany, and (ii) to identify factors associated with DAPT discontinuation during the recommended treatment period. Methods This retrospective cohort study was based on data from a large German electronic healthcare database of the years 2004 to 2009. The study population comprised four groups of patients with acute coronary syndrome (ACS) or stable angina pectoris undergoing inpatient PCI with either ba…

Bare-metal stentmedicine.medical_specialtyAcute coronary syndromeTime Factorsanimal structuresmedicine.medical_treatmentMedicine (miscellaneous)030204 cardiovascular system & hematologyEducation03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineGermanymedicineHumanscardiovascular diseases030212 general & internal medicineRetrospective StudiesInpatientsbusiness.industryHealth PolicyPercutaneous coronary interventionStentDrug-Eluting StentsRetrospective cohort studymedicine.diseaseSurgeryDiscontinuationTreatment OutcomeDrug-eluting stentConventional PCIStentsbusinessPlatelet Aggregation InhibitorsZeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen
researchProduct

The Serine/Threonine Protein Phosphatase 2A (PP2A) Regulates Syk Activity in Human Platelets

2020

Distinct membrane receptors activate platelets by Src-family-kinase (SFK)-, immunoreceptor-tyrosine-based-activation-motif (ITAM)-dependent stimulation of spleen tyrosine kinase (Syk). Recently, we reported that platelet activation via glycoprotein (GP) VI or GPIb&alpha

Blood Platelets0301 basic medicinePlatelet AggregationPhosphataseSykchemical and pharmacologic phenomena030204 cardiovascular system & hematologyenvironment and public healthspleen tyrosine kinase (Syk)ArticleCatalysisInorganic ChemistryDephosphorylationglycoprotein VIglycoprotein Ibα03 medical and health sciences0302 clinical medicineHumansSyk KinaseProtein Phosphatase 2Platelet activationPhosphorylationPhysical and Theoretical ChemistryMolecular BiologySpectroscopyProtein kinase CChemistryKinaseprotein phosphatase 2AOrganic Chemistryhemic and immune systemsGeneral MedicineProtein phosphatase 2Protein-Tyrosine KinasesPlatelet Activation3. Good healthComputer Science ApplicationsCell biologyenzymes and coenzymes (carbohydrates)030104 developmental biologyplateletsPhosphorylationbiological phenomena cell phenomena and immunitySignal TransductionInternational Journal of Molecular Sciences
researchProduct

Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions

2020

Objective: In patients with diabetes mellitus, increased platelet reactivity predicts cardiac events. Limited evidence suggests that DPP-4 (dipeptidyl peptidase 4) influences platelets via GLP-1 (glucagon-like peptide 1)-dependent effects. Because DPP-4 inhibitors are frequently used in diabetes mellitus to improve the GLP-1-regulated glucose metabolism, we characterized the role of DPP-4 inhibition and of native intact versus DPP-4-cleaved GLP-1 on flow-dependent thrombus formation in mouse and human blood. Approach and Results: An ex vivo whole blood microfluidics model was applied to approach in vivo thrombosis and study collagen-dependent platelet adhesion, activation, and thrombus for…

Blood Platelets0301 basic medicineendocrine systemmedicine.medical_specialtyPlatelet AggregationPLATELET ACTIVATIONLinagliptin030204 cardiovascular system & hematologyDPP4Glucagon-Like Peptide-1 Receptorlaw.invention03 medical and health sciences0302 clinical medicinedipeptidyl peptidase 4Fibrinolytic AgentslawInternal medicineDiabetes mellitusmedicineAnimalsHumansPlateletIn patientThrombusglucose610 Medicine &amp; healthDipeptidyl peptidase-4Mice KnockoutDipeptidyl-Peptidase IV InhibitorsChemistryPharmacology. TherapySitagliptin Phosphatedigestive oral and skin physiologyThrombosismedicine.diseaseGlucagon-like peptide-1Peptide Fragmentsglucagon-like peptide 1Mice Inbred C57BLMICE030104 developmental biologyEndocrinologyPhysiological flowdiabetes mellitusplateletsSuppressorHuman medicineCardiology and Cardiovascular MedicineSignal Transduction
researchProduct